The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and womenJ. A. Kanis, Noriko Yoshimura, Claus Christiansen et al.|Osteoporosis International|2007Cited by 1.2k
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH AntagonistHugh S. Taylor, Kristof Chwalisż, Linda C. Giudice et al.|New England Journal of Medicine|2017Cited by 492
Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)Elaine Dennison, Cyrus Cooper, Juliet Compston et al.|Bone|2012Cited by 148
Long-Term Outcomes of Elagolix in Women With EndometriosisEric S. Surrey, Kristof Chwalisż, Hugh S. Taylor et al.|Obstetrics and Gynecology|2018Cited by 132